All In Biotech

Drug Trial Radar · NCT03482232

Consequences of Doing What Should Not be Done in Primary Care

Last checked: Nov 19, 2026Latest source record: Apr 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

750,000

Actual

Start

Oct 14, 2018

Primary completion

Dec 5, 2019

Study completion Feb 10, 2020

Sponsor

Lead sponsor
Universidad Miguel Hernandez de ElcheAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Osasunbidea; Servicio Madrileño de Salud, Madrid, Spain; Fondo de Investigacion Sanitaria; AQuAS; Agencia de Calidad Sanitaria de Andalucía; Ministerio de Sanidad, Servicios Sociales e Igualdad; Servicio Aragones De Salud; Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana; Generalitat Valenciana; MurciaSalud; Osakidetza; Castilla-La Mancha Health Service
First posted
Mar 29, 2018

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Retrospective observational study in a random selection of 5% of digital records active between 2014 and 2017 to quantify the frequency of Do not do primary care recommendations, calculating the over-cost related to them and study reviewing a random selection of cases previously identified to determine whether patient suffered adverse events and their over-cost.

Conditions

  • Overdose
  • Adverse Event

Interventions

  • BenzodiazepinesDrug

    Benzodiazepines for insomnia, agitation or delirium in people older than 65

  • Non-steroidal anti-inflammatory drugsDrug

    Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis

  • paracetamolDrug

    paracetamol 1g for more than 3 days

  • Antimicrobial agentDrug

    antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy

  • Lipid-lowering drugDrug

    Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events

  • Prostate cancerDiagnostic test

    Screening for prostate cancer in asymptomatic patients

  • LumbagoRadiation

    image tests in non-specific lumbago

  • Antimicrobial agentDrug

    antibiotics for pharyngitis (infants)

  • MucolyticDrug

    mucolytics, antitussives or antibiotics for upper respiratory infections (infants)

  • Ibuprofen and paracetamolDrug

    treatment with ibuprofen and paracetamol (infants)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Medical overuseTime frame: Three years
  2. Medical overuseTime frame: Three years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • FISABIO

    Elche, Alicante, Spain

  • Universidad Miguel Hernández

    Elche, Alicante, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.